254905-58-3

Basic information

• Product Name: 1-BOC-4-DIMETHYLCARBAMOYLPIPERIDINE
• Synonyms: 1-BOC-4-DIMETHYLCARBAMOYLPIPERIDINE;tert-butyl 4-(diMethylcarbaMoyl)piperidine-1-carboxylate;N-BOC-4-(dimethylcarbamoyl)piperidine
• CAS NO: 254905-58-3
• Molecular Formula: C₁₃H₂₄N₂O₃
• Molecular Weight: 256.34
• Mol File: 254905-58-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-DIMETHYLCARBAMOYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-DIMETHYLCARBAMOYLPIPERIDINE(254905-58-3)
• EPA Substance Registry System: 1-BOC-4-DIMETHYLCARBAMOYLPIPERIDINE(254905-58-3)

Safety Data

• Hazardous Substances Data: 254905-58-3(Hazardous Substances Data)

Usage

General Description

1-BOC-4-DIMETHYLCARBAMOYLPIPERIDINE is a chemical compound primarily used in organic synthesis and pharmaceutical research. It is a piperidine derivative that contains a BOC (tert-butoxycarbonyl) protected amine group and a dimethylcarbamoyl functional group. The BOC protective group is widely used in organic chemistry to temporarily protect an amine group from unwanted reactions during synthesis, while the dimethylcarbamoyl group is commonly found in bioactive compounds. The compound is stable and compatible with most common organic solvents, making it a versatile building block for the creation of new molecules. Its unique structure and reactivity make 1-BOC-4-DIMETHYLCARBAMOYLPIPERIDINE an important tool for the development of pharmaceuticals and other fine chemicals.

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 124-40-3 dimethyl amine 
• 7647-01-0 hydrogenchloride 
• 39968-33-7 1-hydroxy-7-aza-benzotriazole 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 6270-42-4 N,N-dimethylpiperidine-4-carboxamide hydrochloride 
• 1903-68-0 piperidine-4-carboxylic acid dimethylamide 
• 254905-63-0 {(3E)-4-[N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-((dimethylamino)methyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamoyl]-1,1-dimethylbut-3-enyl}carbamic acid tert-butyl ester 
• 254905-61-8 N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-((dimethylamino)methyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylcarbamic acid tert-butyl ester 
• 254905-62-9 (2R)-N-[(1R)-1-benzyl-2-(4-((dimethylamino)methyl)piperidin-1-yl)-2-oxoethyl]-N-methyl-2-(methylamino)-3-(2-naphthyl)propionamide 
• 254905-59-4 N-[(1R)-1-benzyl-2-(4-((dimethylamino)methyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamic acid tert-butyl ester 
• 172281-72-0 N,N-dimethyl-N-((piperidin-4-yl)methyl)amine dihydrochloride 
• 254905-60-7 (2R)-1-(4-((dimethylamino)methyl)piperidin-1-yl)-2-(methylamino)-3-phenylpropan-1-one 
• 138022-01-2 4-((dimethylamino)methyl)piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agent

In order to identify anti-tubercular agents with a novel scaffold, commercial libraries of small organic compounds were screened against a fluorescent strain of Mycobacterium tuberculosis H37Rv, using a dual phenotypic assay. Compounds were assessed again

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen

WNT signaling is frequently deregulated in malignancy, particularly in colon cancer, and plays a key role in the generation and maintenance of cancer stem cells. We report the discovery and optimization of a 3,4,5-trisubstituted pyridine 9 using a high-throughput cell-based reporter assay of WNT pathway activity. We demonstrate a twisted conformation about the pyridine-piperidine bond of 9 by small-molecule X-ray crystallography. Medicinal chemistry optimization to maintain this twisted conformation, cognisant of physicochemical properties likely to maintain good cell permeability, led to 74 (CCT251545), a potent small-molecule inhibitor of WNT signaling with good oral pharmacokinetics. We demonstrate inhibition of WNT pathway activity in a solid human tumor xenograft model with evidence for tumor growth inhibition following oral dosing. This work provides a successful example of hypothesis-driven medicinal chemistry optimization from a singleton hit against a cell-based pathway assay without knowledge of the biochemical target.

PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and / or prevention of cancer.